Keywords: مهار کننده های PARP; Genomics; high-grade serous ovarian cancer; PARP inhibitors;
مقالات ISI مهار کننده های PARP (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های PARP; Targeted therapy; Anti-angiogenic agents; PARP inhibitors; Immunotherapy; Toxicity;
Keywords: مهار کننده های PARP; antiangiogenics; chemotherapy; epithelial ovarian cancer; PARP inhibitors; targeted therapeutics;
Keywords: مهار کننده های PARP; Triple negative breast cancer; Homologous recombination; Synthetic lethality; PARP; PARP inhibitors;
Keywords: مهار کننده های PARP; Adverse events; DNA repair; PARP inhibitors; Secondary malignancy; Treatment-related leukemia;
Keywords: مهار کننده های PARP; Genetic counseling; Genetic testing; Ovarian cancer; PARP inhibitors; BRCA1; BRCA2;
Keywords: مهار کننده های PARP; Ovarian cancer; Genomics; Molecular subtype; Target therapy; Angiogenesis inhibitors; PARP inhibitors; Anti-folate receptor treatment; Anti-cancer stem cells treatment;
Keywords: مهار کننده های PARP; PARP inhibitors; DNA repair; Homologous recombination repair; HRD; Homologous recombination deficiency; BRCA1; BRCA2; Ovarian cancer; Olaparib;
Keywords: مهار کننده های PARP; Triple-negative breast cancer BRCA1/2 Next-generation sequencing; Cancer genetics; PARP inhibitors;
Keywords: مهار کننده های PARP; High-grade serous ovarian cancer; Platinum; Chemotherapy; Resistance; p53; BRCA1; BRCA2; PARP inhibitors; Patient-derived xenografts
Keywords: مهار کننده های PARP; Ovarian cancer; Surgical debulking; Chemotherapy; BRCA1; BRCA2; Bevacizumab; PARP inhibitors; Immunotherapy;
Keywords: مهار کننده های PARP; DIQ; 1,5-dihydroxyisoquinoline; 4-AN; 4-amino-1,8-naphthalimide; 6,4PPs; 6,4-photoproducts; 8-oxodG; 8-oxo-2â²-deoxyguanosine; OGG1; 8-oxoguanine glycosylase 1; APE1; AP-endonuclease; ATM; ataxia telangiectasia-mutated gene; BER; base excision repair; BR
Keywords: مهار کننده های PARP; Ovarian cancer; Targeted therapy; Anti-angiogenic therapy; PARP inhibitors; Immunotherapy; Intraperitoneal chemotherapy;
Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells
Keywords: مهار کننده های PARP; HPLC-UV-DAD; Bioanalytical method validation; Intracellular drug concentration; PARP inhibitors; Olaparib;
The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis
Keywords: مهار کننده های PARP; Ovarian cancer; PARP inhibitors; Maintenance therapy; Randomized clinical trials; Meta-analysis;
PARP activity and inhibition in fetal and adult oligodendrocyte precursor cells: Effect on cell survival and differentiation
Keywords: مهار کننده های PARP; Oligodendrocyte precursor cells; Neonatal hypoxic/ischemic encephalopathy; PARP inhibitors; Remyelination;
Design, synthesis and biological activity of novel molecules designed to target PARP and DNA
Keywords: مهار کننده های PARP; PARP inhibitors; BRCA mutation; Synthetic lethality; DNA damage; Bis-targeting;
BRCA mutation genetic testing implications in the United States
Keywords: مهار کننده های PARP; BRCA1; BRCA2; Genetic testing; Timing; Hereditary breast cancer; Prophylactic mastectomy; Prophylactic oophorectomy; PARP inhibitors; Platinums;
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Keywords: مهار کننده های PARP; PARP inhibitors; BRCA1/2 mutation; Therapy resistance; Ovarian cancer;
Targeting DNA damage in SCLC
Keywords: مهار کننده های PARP; Lung Cancer; Small Cell Lung Cancer; DNA Repair Pathways; PARP Inhibitors; Checkpoint Inhibitors;
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic
Keywords: مهار کننده های PARP; Epithelial ovarian cancer; BRCA; Base excision repair; Homologous recombination deficiency; PARP inhibitors; Anti-angiogenic agents; Immune checkpoint inhibitors;
Development of PARP inhibitors in gynecological malignancies
Keywords: مهار کننده های PARP; PARP inhibitors; homologous recombination deficiency; BRCAness; biomarkers;
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Keywords: مهار کننده های PARP; HRÂ + BC; HER2Â + BC; Triple negative BC; PARP inhibitors; PI3K-AKT-mTOR pathway; PI3K-mTOR inhibitors;
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Keywords: مهار کننده های PARP; Poly(ADP-ribose) polymerase; Synthetic lethality; PARP; DNA repair; PARP inhibitors;
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy
Keywords: مهار کننده های PARP; Antitumor drug; BRCA1/2; PARP inhibitors; Molecular docking;
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study
Keywords: مهار کننده های PARP; PARP inhibitors; VEGF inhibitors; Thrombocytopenia;
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Keywords: مهار کننده های PARP; BRCA1/2; BRCA1 or BRCA2; CDK; cyclin-dependent kinase; FBS; heat-inactivated fetal bovine serum; HGSOC; high-grade serous ovarian carcinoma; HR; homologous recombination; IP; intraperitoneal; pADPr; poly(ADP-ribose) polymer; PARP; poly(ADP-ribose) polymer
Review ArticleBeyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer
Keywords: مهار کننده های PARP; anti-angiogenesis; cervical cancer; immunotherapy; PARP inhibitors; targeted therapy;
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences
Keywords: مهار کننده های PARP; Poly(ADP-ribose); PARP inhibitors; Sulfur mustard; Nitrogen mustard; Genotoxicity; HaCaT; Mass spectrometry; Micronucleus;
DNA repair targeted therapy: The past or future of cancer treatment?
Keywords: مهار کننده های PARP; DNA damage; DNA repair; Cancer; Radiation; Replication protein A; NER; nucleotide excision repair; MMR; DNA mismatch repair; BER; base excision repair; HDR; homology directed repair; FA; Fanconi anemia; HR; homologous recombination; DDR; DNA damage respon
PARP inhibitors: A new era of targeted therapy
Keywords: مهار کننده های PARP; PARP inhibitors; Lynparza; Olaparib; BMN-673; Personalized medicine;
In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio
Keywords: مهار کننده های PARP; Prostate cancer; PARP inhibitors; AZD-2281; Gut toxicity; EF5; Gamma H2AX; Clonogenic assay; Growth delay;
De la découverte du poly(ADP-ribose) aux inhibiteurs PARP en thérapie du cancer
Keywords: مهار کننده های PARP; Poly(ADP-ribose) polymérase; Inhibiteurs PARP; Réparation de l'ADN; Chimio- et radiothérapie; BRCA1/2; Létalité synthétique; Poly(ADP-ribose) polymerase; PARP inhibitors; DNA repair; Chemo- and radiotherapy; BRCA1/2; Synthetic lethality;
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma
Keywords: مهار کننده های PARP; Anaplastic thyroid carcinoma; Oncolytic virus; PARP inhibitors;
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
Keywords: مهار کننده های PARP; PARP inhibitors; MSI; MRE11; DNA damage; Colorectal cancer;
Les formes héréditaires du cancer de l'ovaire : particularités clinico-biologiques et thérapeutiques
Keywords: مهار کننده های PARP; cancer de l'ovaire; syndrome sein-ovaire; syndrome de Lynch; poly (ADP-ribose) polymérase; inhibiteurs de parp; hereditary ovarian cancer; hereditary breast ovarian cancer; Lynch syndrom; Parp inhibitors;
PARP inhibitors in ovarian cancer: Current status and future promise
Keywords: مهار کننده های PARP; PARP inhibitors; BRCA; Ovarian cancer;
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors
Keywords: مهار کننده های PARP; PARP inhibitors; Synthesis; Molecular modelling; 7-Azaindoles; Antitumor;
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Keywords: مهار کننده های PARP; Poly(ADP-ribose) polymerase; DNA repair; Chromatin response; Cancer; PARP inhibitors
The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest
Keywords: مهار کننده های PARP; Poly(ADP)-ribose polymerase; PARP inhibitors; p21; Breast cancer; Cell cycle checkpoint;
Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives
Keywords: مهار کننده های PARP; Metastatic breast cancer; Endocrine treatment; Aromatase inhibitors; Chemotherapy; Anthracyclines; Taxanes; Anti-ErbB2 targeted therapy; Anti-angiogenesis; PARP inhibitors; Anti-EGFR; Bisphosphonates; Anti-RANKL; Palliation; Survival
Targeted trials in ovarian cancer
Keywords: مهار کننده های PARP; Molecular targeted therapy; Ovarian cancer; Angiogenesis; Bevacizumab; PARP inhibitors
Novel Treatment Approaches for Triple-Negative Breast Cancer
Keywords: مهار کننده های PARP; Angiogenesis inhibitors; BRCA; DNA repair; PARP inhibitors
Male breast cancer: An update in diagnosis, treatment and molecular profiling
Keywords: مهار کننده های PARP; Male breast cancer; BRCA; PARP inhibitors; Olaparib; HER2; Estrogen receptor; Progesterone receptor; Trastuzumab; Trastuzumab-DM1
Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes « triple zéro/BRCA1-like »
Keywords: مهار کننده های PARP; carcinomes basal-like; BRCA1; cancer du sein; profil d'expression; immunophénotype; inhibiteurs de PARP; basal-like carcinoma; breast cancer; gene expression profiling; phenotype; PARP inhibitors;
Targeting DNA repair in breast cancer: A clinical and translational update
Keywords: مهار کننده های PARP; Breast cancer; PARP inhibitors; Triple negative; BRCA1; BRCA2
Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer
Keywords: مهار کننده های PARP; Angiogenesis inhibitors; BRCA1; Monoclonal antibodies; mTOR; PARP inhibitors
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
Keywords: مهار کننده های PARP; Breast cancer; Triple negative; Basal-like; Molecular features; Breast epithelium; Molecular targets; Platinum compounds; PARP inhibitors; EGFR inhibitors; Antiangiogenics
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
Keywords: مهار کننده های PARP; PARP-1; Apoptosis; Necrosis; DNA repair; PARP inhibitors;
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Keywords: مهار کننده های PARP; PARP inhibitors; BRCA1; BRCA2; Homologous recombination; Single-strand break repair; Double-strand break repair